AVANIR (AVNR) Higher As Phase III Trial Meets Efficacy Endpoint
Up)AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) is seeing upside action today after the company announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).
Over the course of the 12-week study, Zenvia 30/10 mg and 20/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 47.2% and 47.8% respectively, beyond placebo (p<0.0001).
Shares of AVNR are up 11% currently.
More from Release
You May Also Be Interested In
- Biosante Pharma (BPAX) Volatility Up as Shares Run Nearly 50%
- Medicis (MRX) Gets Verbal Notice of Allowance for ZYCLARA Patent on Actinic Keratosis
- Marriot (VAC) Leisurely Makes New Highs
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
